{
    "hands_on_practices": [
        {
            "introduction": "Effective chronic viral suppression relies on maintaining a consistent therapeutic concentration of the drug in the body. This first exercise grounds your understanding in the fundamental pharmacokinetic principle of steady state, where the rate of drug administration equals the rate of elimination. By deriving the equation for average steady-state concentration from basic definitions, you will build a quantitative framework for understanding how dosing regimens are designed and why they must be adjusted in situations like renal impairment .",
            "id": "4918148",
            "problem": "A patient with chronic Hepatitis B virus (HBV) infection is treated with tenofovir disoproxil fumarate (TDF). Assume linear pharmacokinetics, immediate absorption relative to the dosing interval, and attainment of steady state under multiple oral dosing. Use only fundamental pharmacokinetic definitions: steady state implies equality of average input and average output over each dosing interval, the systemic clearance $CL$ is defined by $CL = \\frac{\\text{rate of elimination}}{C}$, and oral dosing results in average input rate over the dosing interval of $F$ times the dose per unit time.\n\nTask 1 (derivation): Starting from these definitions, derive an expression for the average steady-state plasma concentration over a dosing interval, $C_{ss,\\text{avg}}$, in terms of the oral bioavailability $F$, oral dose per administration $D$, systemic clearance $CL$, and dosing interval $\\tau$. Do not substitute numerical values until after you have obtained the general expression.\n\nTask 2 (application to renal impairment): In a typical adult with normal renal function receiving TDF, let $D = 300$ mg, $F = 0.25$, $CL_{\\text{normal}} = 8.0$ L/h, and $\\tau = 24$ h. In moderate renal impairment, assume the clearance is reduced such that $CL_{\\text{imp}} = 0.55\\, CL_{\\text{normal}}$, with $F$, $D$, and $\\tau$ unchanged. Using your derived expression, compute the fold-change\n$$R = \\frac{C_{ss,\\text{avg}}(\\text{impaired})}{C_{ss,\\text{avg}}(\\text{normal})}.$$\nExpress $R$ as a pure number (unitless) and round your answer to three significant figures.\n\nYour reasoning should explain how the mass-balance and clearance definitions lead to your expression for $C_{ss,\\text{avg}}$, and why a change in $CL$ due to renal impairment affects $C_{ss,\\text{avg}}$ for TDF, which is predominantly renally eliminated. Do not report any intermediate numerical values in the final answer; only report the requested $R$.",
            "solution": "### Task 1: Derivation of the Expression for $C_{ss,\\text{avg}}$\n\nThe derivation begins from the fundamental principle of mass balance at steady state. For a drug administered in multiple doses, steady state is the condition where the amount of drug entering the body over a dosing interval is equal to the amount of drug eliminated from the body over the same interval. This can be expressed as:\n$$\n\\text{Average Rate of Drug Input} = \\text{Average Rate of Drug Elimination}\n$$\n\nThe problem statement provides definitions to formalize both sides of this equality.\n\n**1. Average Rate of Drug Input:**\nFor an oral dose $D$ administered every $\\tau$ time units, not all of the dose may reach the systemic circulation due to incomplete absorption and/or first-pass metabolism. The fraction that reaches the systemic circulation is the oral bioavailability, $F$. The total amount of drug entering the systemic circulation per dosing interval is thus $F \\times D$. The average rate of input over the dosing interval $\\tau$ is therefore given by:\n$$\n\\text{Average Rate of Input} = \\frac{F \\times D}{\\tau}\n$$\n\n**2. Average Rate of Drug Elimination:**\nThe problem defines systemic clearance, $CL$, as the constant of proportionality relating the rate of elimination to the plasma concentration, $C(t)$:\n$$\n\\text{Rate of Elimination}(t) = CL \\times C(t)\n$$\nThis relationship holds for linear pharmacokinetics, as assumed. The average rate of elimination over a dosing interval from time $t_1$ to $t_1 + \\tau$ is the integral of the instantaneous rate of elimination divided by the duration of the interval:\n$$\n\\text{Average Rate of Elimination} = \\frac{1}{\\tau} \\int_{t_1}^{t_1+\\tau} \\text{Rate of Elimination}(t) \\, dt = \\frac{1}{\\tau} \\int_{t_1}^{t_1+\\tau} CL \\times C(t) \\, dt\n$$\nSince clearance $CL$ is a constant, it can be moved outside the integral:\n$$\n\\text{Average Rate of Elimination} = CL \\times \\left( \\frac{1}{\\tau} \\int_{t_1}^{t_1+\\tau} C(t) \\, dt \\right)\n$$\nThe term in the parentheses is, by definition, the average steady-state plasma concentration over the dosing interval, $C_{ss,\\text{avg}}$. Thus:\n$$\n\\text{Average Rate of Elimination} = CL \\times C_{ss,\\text{avg}}\n$$\n\n**3. Equating Rates and Solving for $C_{ss,\\text{avg}}$:**\nBy equating the average rate of input with the average rate of output at steady state, we obtain:\n$$\n\\frac{F \\times D}{\\tau} = CL \\times C_{ss,\\text{avg}}\n$$\nSolving for $C_{ss,\\text{avg}}$ yields the desired general expression:\n$$\nC_{ss,\\text{avg}} = \\frac{F \\times D}{CL \\times \\tau}\n$$\n\n### Task 2: Application to Renal Impairment\n\nThe derived expression shows that the average steady-state concentration is directly proportional to the dose $D$ and bioavailability $F$, and inversely proportional to the systemic clearance $CL$ and the dosing interval $\\tau$.\n\n**1. Calculating the Fold-Change Ratio $R$:**\nWe are asked to compute the ratio $R$, defined as:\n$$\nR = \\frac{C_{ss,\\text{avg}}(\\text{impaired})}{C_{ss,\\text{avg}}(\\text{normal})}\n$$\nUsing the derived formula, we can write the expressions for the average steady-state concentration in patients with normal and impaired renal function.\n\nFor a patient with normal renal function, the clearance is $CL_{\\text{normal}}$:\n$$\nC_{ss,\\text{avg}}(\\text{normal}) = \\frac{F \\times D}{CL_{\\text{normal}} \\times \\tau}\n$$\n\nFor a patient with moderate renal impairment, the clearance is reduced to $CL_{\\text{imp}}$. The problem states that the dose $D$, bioavailability $F$, and dosing interval $\\tau$ remain unchanged:\n$$\nC_{ss,\\text{avg}}(\\text{impaired}) = \\frac{F \\times D}{CL_{\\text{imp}} \\times \\tau}\n$$\n\nNow, we substitute these expressions into the ratio $R$:\n$$\nR = \\frac{\\left(\\frac{F \\times D}{CL_{\\text{imp}} \\times \\tau}\\right)}{\\left(\\frac{F \\times D}{CL_{\\text{normal}} \\times \\tau}\\right)}\n$$\nThe terms $F$, $D$, and $\\tau$ are common to both the numerator and the denominator, and thus cancel out, simplifying the expression to:\n$$\nR = \\frac{CL_{\\text{normal}}}{CL_{\\text{imp}}}\n$$\nThis result demonstrates that the fold-change in average steady-state concentration is equal to the inverse of the fold-change in clearance.\n\nThe problem states that for moderate renal impairment, $CL_{\\text{imp}} = 0.55 \\times CL_{\\text{normal}}$. Substituting this relationship into the expression for $R$:\n$$\nR = \\frac{CL_{\\text{normal}}}{0.55 \\times CL_{\\text{normal}}}\n$$\nThe term $CL_{\\text{normal}}$ cancels, leaving a purely numerical ratio:\n$$\nR = \\frac{1}{0.55}\n$$\nPerforming the division gives:\n$$\nR \\approx 1.818181...\n$$\nRounding to three significant figures, as requested, we get:\n$$\nR \\approx 1.82\n$$\n\n**2. Pharmacological Rationale:**\nTenofovir disoproxil fumarate (TDF) is a prodrug of tenofovir, which is primarily eliminated from the body by the kidneys through a combination of glomerular filtration and active tubular secretion. Systemic clearance ($CL$) is the sum of clearance by all organs, but for a drug like tenofovir, renal clearance ($CL_R$) is the major component of systemic clearance ($CL \\approx CL_R$). Renal impairment, which signifies a decline in kidney function, directly leads to a reduction in the renal clearance of drugs. Consequently, the systemic clearance of tenofovir is significantly reduced.\n\nAs shown by the derived relationship $C_{ss,\\text{avg}} = \\frac{F \\times D}{CL \\times \\tau}$, a decrease in $CL$ with an unchanged dosing regimen ($F, D, \\tau$) will cause a proportional increase in the average steady-state plasma concentration. This increased drug exposure can heighten the risk of concentration-dependent adverse effects, such as nephrotoxicity, which is a known concern with tenofovir. Therefore, in clinical practice, the dose or the dosing interval for renally eliminated drugs like TDF is adjusted in patients with renal impairment to maintain drug exposure within the therapeutic window and avoid toxicity. The calculated fold-change $R \\approx 1.82$ quantifies this increase in exposure, suggesting that drug accumulation will be nearly $82\\%$ higher in a patient with moderate renal impairment if the standard dosing regimen is continued.",
            "answer": "$$\\boxed{1.82}$$"
        },
        {
            "introduction": "While systemic drug levels are important, the ultimate antiviral effect depends on the concentration and persistence of the active drug within the target cells. This practice shifts the focus from the plasma to the intracellular environment, specifically within hepatocytes for Hepatitis B therapy. You will calculate the exceptionally long intracellular half-life of tenofovir's active metabolite and explore how this property provides crucial 'forgiveness' for occasional missed doses, a key factor in long-term treatment success .",
            "id": "4918133",
            "problem": "Tenofovir diphosphate (TFV-DP) is the active intracellular metabolite generated from the prodrugs tenofovir disoproxil fumarate and tenofovir alafenamide used in therapy for Hepatitis B virus (HBV). In hepatocytes, intracellular elimination of TFV-DP is well-described by first-order kinetics. Consider a hepatocyte compartment in which the intracellular TFV-DP amount, denoted by $A(t)$, is governed by a constant first-order decay rate with rate constant $k$. Starting from the definition of first-order decay and the operational definition of half-life as the time required for $A(t)$ to reduce to one-half its initial value, derive an expression for the intracellular half-life in terms of $k$ and then compute its numerical value for $k = 0.110\\,\\text{day}^{-1}$. Round your answer to three significant figures and express the half-life in days. In your reasoning, explain how the resulting half-life would influence the forgiveness of missed once-daily doses in chronic HBV therapy without introducing any additional empirical formulas beyond first-order decay and the definition of half-life.",
            "solution": "The intracellular elimination of Tenofovir diphosphate (TFV-DP) is described by first-order kinetics. The rate of change of the amount of TFV-DP, $A(t)$, is directly proportional to the amount present at time $t$. This relationship is expressed by the following first-order ordinary differential equation:\n$$\n\\frac{dA(t)}{dt} = -k A(t)\n$$\nwhere $k$ is the first-order elimination rate constant. The negative sign indicates that the amount of the substance is decreasing over time.\n\nTo find the amount $A(t)$ as a function of time, we solve this differential equation. We can separate the variables:\n$$\n\\frac{1}{A(t)} dA(t) = -k \\, dt\n$$\nWe integrate both sides of the equation. Let the initial amount of TFV-DP at time $t=0$ be $A_0$. We integrate from the initial state $(0, A_0)$ to a state at time $t$, $(t, A(t))$:\n$$\n\\int_{A_0}^{A(t)} \\frac{1}{A'} dA' = \\int_{0}^{t} -k \\, d\\tau\n$$\nExecuting the integration yields:\n$$\n\\ln(A(t)) - \\ln(A_0) = -kt\n$$\nUsing the properties of logarithms, we can write this as:\n$$\n\\ln\\left(\\frac{A(t)}{A_0}\\right) = -kt\n$$\nTo solve for $A(t)$, we exponentiate both sides:\n$$\n\\frac{A(t)}{A_0} = \\exp(-kt)\n$$\n$$\nA(t) = A_0 \\exp(-kt)\n$$\nThis equation describes the exponential decay of TFV-DP in the hepatocyte.\n\nThe half-life, denoted $t_{1/2}$, is defined as the time required for the amount of the substance to be reduced to one-half of its initial value. According to this definition, at $t = t_{1/2}$, the amount $A(t_{1/2})$ is equal to $\\frac{A_0}{2}$. We substitute this condition into our decay equation:\n$$\n\\frac{A_0}{2} = A_0 \\exp(-k t_{1/2})\n$$\nAssuming $A_0 > 0$, we can divide both sides by $A_0$:\n$$\n\\frac{1}{2} = \\exp(-k t_{1/2})\n$$\nTo solve for $t_{1/2}$, we take the natural logarithm of both sides:\n$$\n\\ln\\left(\\frac{1}{2}\\right) = -k t_{1/2}\n$$\nSince $\\ln(\\frac{1}{2}) = -\\ln(2)$, the equation becomes:\n$$\n-\\ln(2) = -k t_{1/2}\n$$\nSolving for $t_{1/2}$ yields the general expression for the half-life in a first-order process:\n$$\nt_{1/2} = \\frac{\\ln(2)}{k}\n$$\nNow, we compute the numerical value of the half-life given the rate constant $k = 0.110\\,\\text{day}^{-1}$. Substituting this value into our derived expression:\n$$\nt_{1/2} = \\frac{\\ln(2)}{0.110\\,\\text{day}^{-1}}\n$$\nUsing the value $\\ln(2) \\approx 0.693147$, we calculate:\n$$\nt_{1/2} \\approx \\frac{0.693147}{0.110} \\, \\text{days} \\approx 6.301336... \\, \\text{days}\n$$\nRounding the result to three significant figures, as dictated by the precision of the given rate constant $k$:\n$$\nt_{1/2} \\approx 6.30 \\, \\text{days}\n$$\n\nThe influence of this half-life on the forgiveness of missed once-daily doses can be explained directly from the principles of first-order decay. A half-life of $6.30$ days is substantially longer than the once-daily dosing interval of $1$ day. This long half-life implies a very slow rate of elimination from the target cells (hepatocytes). The fraction of TFV-DP remaining after one dosing interval ($t=1\\,\\text{day}$) can be calculated as $\\frac{A(1)}{A(0)} = \\exp(-kt) = \\exp(-0.110 \\times 1) \\approx 0.896$. This means that at the time of the next scheduled dose, approximately $89.6\\%$ of the intracellular drug from the previous dose is still present. If a patient misses a dose, an additional day passes. The amount remaining after $2$ days from the last-taken dose would be $\\exp(-0.110 \\times 2) \\approx 0.803$, or about $80.3\\%$ of the peak level from that dose. Because the intracellular concentration of the active metabolite TFV-DP declines so slowly, it is highly likely to remain above the minimum effective concentration required to suppress viral replication, even after a single missed dose. This slow decay provides a \"forgiveness\" window, making the therapy robust to occasional non-adherence. A drug with a short half-life relative to its dosing interval would experience a rapid drop in concentration, potentially falling below therapeutic levels and risking treatment failure or the development of drug resistance. Thus, a long intracellular half-life is a highly desirable pharmacokinetic property for agents used in chronic viral suppression.",
            "answer": "$$\n\\boxed{6.30}\n$$"
        },
        {
            "introduction": "Pharmacodynamics provides the crucial link between a drug's mechanism and its observable effect on the body or a pathogen. This final practice utilizes a foundational viral kinetics model to simulate the early phase of antiviral therapy for Hepatitis B. By solving for the time course of viral load decline, you will gain a dynamic perspective on how a drug's efficacy directly translates into the speed and magnitude of viral suppression, a primary goal of treatment .",
            "id": "4918159",
            "problem": "A patient with chronic Hepatitis B Virus (HBV) infection has a measurable plasma HBV deoxyribonucleic acid (DNA) concentration denoted by $V(t)$ in International Units (IU) per milliliter $\\mathrm{mL}^{-1}$. In a single-compartment mass-balance model of viral kinetics, the time evolution of $V(t)$ under treatment with a reverse transcriptase (polymerase) inhibitor of efficacy $E$ is modeled by the ordinary differential equation (ODE)\n$$\\frac{dV}{dt} = p(1 - E)I - cV,$$\nwhere $p$ is the per-cell virion production rate, $I$ is the infected cell count (assumed constant over the short, early phase of treatment), and $c$ is the first-order clearance rate constant of circulating virus.\n\nBefore therapy ($t < 0$), assume $E = 0$ and the system is at steady state. At $t = 0$, the inhibitor is initiated and $E$ instantaneously steps to a constant value. Using fundamental mass-balance principles and the ODE above, derive the expression for the time course $V(t)$ for $t \\geq 0$ and then compute the time $t_{100}$ (in days) required for a $2$-log decline (i.e., a $100$-fold reduction) from the pre-therapy baseline $V(0)$.\n\nUse the following parameter values:\n- $p = 50\\ \\mathrm{IU}\\cdot\\mathrm{day}^{-1}\\cdot\\mathrm{cell}^{-1}$,\n- $I = 10^{5}\\ \\mathrm{cells}\\cdot\\mathrm{mL}^{-1}$,\n- $c = 1.0\\ \\mathrm{day}^{-1}$,\n- $E = 0.995$.\n\nExpress your final numerical answer for $t_{100}$ in days and round to four significant figures.",
            "solution": "### Derivation of the Solution\n\n**Part 1: Determine the Initial Condition $V(0)$**\n\nBefore the initiation of therapy (for $t < 0$), the system is at steady state, which means the viral load is constant, so $\\frac{dV}{dt} = 0$. During this period, the drug efficacy is $E=0$. Substituting these conditions into the governing ODE:\n$$0 = p(1 - 0)I - cV_{\\text{baseline}}$$\n$$0 = pI - cV_{\\text{baseline}}$$\nSolving for the baseline viral load, $V_{\\text{baseline}}$, gives the initial condition for the treatment phase at $t=0$:\n$$V(0) = V_{\\text{baseline}} = \\frac{pI}{c}$$\n\n**Part 2: Solve the ODE for $t \\geq 0$**\n\nFor $t \\geq 0$, therapy is active with efficacy $E = 0.995$. The ODE is:\n$$\\frac{dV}{dt} = p(1 - E)I - cV$$\nThis is a first-order linear ODE. We can rearrange it into the standard form $\\frac{dy}{dx} + P(x)y = Q(x)$:\n$$\\frac{dV}{dt} + cV = p(1 - E)I$$\nHere, the integrating factor $\\mu(t)$ is given by $\\mu(t) = \\exp\\left(\\int c \\, dt\\right) = \\exp(ct)$. Multiplying the entire equation by $\\mu(t)$:\n$$\\exp(ct)\\frac{dV}{dt} + c\\exp(ct)V = p(1 - E)I\\exp(ct)$$\nThe left side is the derivative of the product $V(t)\\exp(ct)$ with respect to $t$:\n$$\\frac{d}{dt}\\left(V(t)\\exp(ct)\\right) = p(1 - E)I\\exp(ct)$$\nIntegrating both sides with respect to $t$:\n$$V(t)\\exp(ct) = \\int p(1 - E)I\\exp(ct) \\, dt$$\n$$V(t)\\exp(ct) = \\frac{p(1 - E)I}{c}\\exp(ct) + K$$\nwhere $K$ is the constant of integration. To find the general solution for $V(t)$, we divide by $\\exp(ct)$:\n$$V(t) = \\frac{p(1 - E)I}{c} + K\\exp(-ct)$$\nNow, we apply the initial condition $V(0) = \\frac{pI}{c}$ to determine $K$:\n$$V(0) = \\frac{p(1 - E)I}{c} + K\\exp(-c \\cdot 0)$$\n$$\\frac{pI}{c} = \\frac{pI}{c} - \\frac{pEI}{c} + K$$\nSolving for $K$:\n$$K = \\frac{pEI}{c}$$\nSubstituting this value of $K$ back into the general solution gives the specific solution for the viral load time course for $t \\geq 0$:\n$$V(t) = \\frac{p(1 - E)I}{c} + \\frac{pEI}{c}\\exp(-ct)$$\n\n**Part 3: Compute the Time for a $100$-fold Reduction, $t_{100}$**\n\nWe need to find the time $t_{100}$ such that $V(t_{100}) = \\frac{V(0)}{100}$. Using the expressions for $V(t)$ and $V(0)$:\n$$\\frac{p(1 - E)I}{c} + \\frac{pEI}{c}\\exp(-ct_{100}) = \\frac{1}{100}\\left(\\frac{pI}{c}\\right)$$\nWe can divide the entire equation by the non-zero term $\\frac{pI}{c}$:\n$$(1 - E) + E\\exp(-ct_{100}) = \\frac{1}{100}$$\nNow, we solve for $t_{100}$. Rearranging the terms to isolate the exponential:\n$$E\\exp(-ct_{100}) = \\frac{1}{100} - (1 - E)$$\n$$E\\exp(-ct_{100}) = \\frac{1}{100} - 1 + E$$\n$$E\\exp(-ct_{100}) = E - \\frac{99}{100}$$\n$$\\exp(-ct_{100}) = \\frac{E - \\frac{99}{100}}{E} = 1 - \\frac{99}{100E}$$\nTaking the natural logarithm of both sides:\n$$-ct_{100} = \\ln\\left(1 - \\frac{99}{100E}\\right)$$\nFinally, solving for $t_{100}$:\n$$t_{100} = -\\frac{1}{c}\\ln\\left(1 - \\frac{99}{100E}\\right)$$\n\n**Part 4: Substitute Numerical Values**\n\nNow we substitute the given parameter values: $c = 1.0\\ \\mathrm{day}^{-1}$ and $E = 0.995$.\n$$t_{100} = -\\frac{1}{1.0}\\ln\\left(1 - \\frac{99}{100 \\times 0.995}\\right)$$\n$$t_{100} = -\\ln\\left(1 - \\frac{99}{99.5}\\right)$$\n$$t_{100} = -\\ln\\left(\\frac{99.5 - 99}{99.5}\\right)$$\n$$t_{100} = -\\ln\\left(\\frac{0.5}{99.5}\\right)$$\n$$t_{100} = -\\ln\\left(\\frac{1}{199}\\right)$$\nUsing the property of logarithms $\\ln(1/x) = -\\ln(x)$:\n$$t_{100} = \\ln(199)$$\nCalculating the numerical value:\n$$t_{100} \\approx 5.2933045...$$\nRounding to four significant figures as required by the problem statement:\n$$t_{100} \\approx 5.293\\ \\mathrm{days}$$",
            "answer": "$$\\boxed{5.293}$$"
        }
    ]
}